All systems go as US UDI deadline looms: FDA fine-tunes provisions
This article was originally published in Clinica
Executive Summary
Jay Crowley , senior advisor to the US FDA on patient safety, explains how the agency is faring with its mandate to introduce a unique device identification system in the country. Neena Brizmohun, of Clinica’s sister publication Scrip Regulatory Affairs, reports
You may also be interested in...
Medtronic Wins In England’s NICE Decision On Implantable Monitors For Stroke Patients; Biotronik And Abbott Lose
UK health technology assessment body NICE says that Medtronic’s Reveal LINQ, which transmits data remotely to doctors, is likely to be a cost-effective use of National Health Service resources.
Denmark To Adopt QALY For Cost-Effectiveness Assessments
Using the QALY is expected to help the Danish Medicines Council make its decisions on the cost effectiveness of drugs more transparent, but it will also extend the time the council takes to make a recommendation.
Italy: Companies Advised To Prepare Now For Industry Transparency Rule
Members of Italian industry body Confindustria Dispositivi Medici should insert a suitable transparency clause in their agreements with health care professionals, says law firm Osborne Clarke, after the trade association introduced a new requirement relating to payments to HPCs.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: